Walleye Capital LLC grew its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating) by 1,241.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,937 shares of the company’s stock after acquiring an additional 148,938 shares during the period. Walleye Capital LLC’s holdings in Lyell Immunopharma were worth $813,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Lyell Immunopharma by 309.6% in the first quarter. Vanguard Group Inc. now owns 8,778,702 shares of the company’s stock valued at $44,332,000 after purchasing an additional 6,635,614 shares during the period. BlackRock Inc. lifted its holdings in shares of Lyell Immunopharma by 290.6% in the 1st quarter. BlackRock Inc. now owns 7,809,490 shares of the company’s stock worth $39,438,000 after buying an additional 5,810,038 shares during the period. State Street Corp grew its position in shares of Lyell Immunopharma by 351.1% during the 1st quarter. State Street Corp now owns 1,890,929 shares of the company’s stock worth $9,549,000 after buying an additional 1,471,745 shares in the last quarter. MIC Capital Management UK LLP bought a new position in shares of Lyell Immunopharma during the 4th quarter worth $10,217,000. Finally, Northern Trust Corp increased its stake in shares of Lyell Immunopharma by 397.4% during the first quarter. Northern Trust Corp now owns 1,052,410 shares of the company’s stock valued at $5,315,000 after buying an additional 840,833 shares during the period. 40.25% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group lowered their price objective on shares of Lyell Immunopharma from $21.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th.
Lyell Immunopharma Stock Up 1.9 %
Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.16. The firm had revenue of $35.74 million during the quarter, compared to analysts’ expectations of $3.37 million. Lyell Immunopharma had a negative return on equity of 25.87% and a negative net margin of 566.14%. On average, sell-side analysts expect that Lyell Immunopharma, Inc. will post -1.15 EPS for the current year.
Lyell Immunopharma Profile
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
- Get a free copy of the StockNews.com research report on Lyell Immunopharma (LYEL)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.